- Home
- LBTYB vs ACAD Comparison
LBTYB vs ACAD Comparison
Compare LBTYB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYB
- ACAD
- Stock Information
- Founded
- LBTYB 2004
- ACAD 1993
- Country
- LBTYB Bermuda
- ACAD United States
- Employees
- LBTYB N/A
- ACAD N/A
- Industry
- LBTYB Cable & Other Pay Television Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYB Telecommunications
- ACAD Health Care
- Exchange
- LBTYB Nasdaq
- ACAD Nasdaq
- Market Cap
- LBTYB 3.4B
- ACAD 3.8B
- IPO Year
- LBTYB N/A
- ACAD 2004
- Fundamental
- Price
- LBTYB $9.57
- ACAD $21.24
- Analyst Decision
- LBTYB
- ACAD Buy
- Analyst Count
- LBTYB 0
- ACAD 19
- Target Price
- LBTYB N/A
- ACAD $27.89
- AVG Volume (30 Days)
- LBTYB 752.0
- ACAD 1.9M
- Earning Date
- LBTYB 01-01-0001
- ACAD 08-05-2025
- Dividend Yield
- LBTYB N/A
- ACAD N/A
- EPS Growth
- LBTYB N/A
- ACAD N/A
- EPS
- LBTYB N/A
- ACAD 1.37
- Revenue
- LBTYB $4,421,800,000.00
- ACAD $996,283,000.00
- Revenue This Year
- LBTYB $8.29
- ACAD $13.39
- Revenue Next Year
- LBTYB $0.74
- ACAD $10.59
- P/E Ratio
- LBTYB N/A
- ACAD $15.53
- Revenue Growth
- LBTYB 32.44
- ACAD 22.42
- 52 Week Low
- LBTYB $9.15
- ACAD $13.40
- 52 Week High
- LBTYB $21.90
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- LBTYB 44.31
- ACAD 52.31
- Support Level
- LBTYB $9.58
- ACAD $21.39
- Resistance Level
- LBTYB $10.41
- ACAD $23.09
- Average True Range (ATR)
- LBTYB 0.13
- ACAD 0.76
- MACD
- LBTYB -0.00
- ACAD -0.27
- Stochastic Oscillator
- LBTYB 10.64
- ACAD 17.99
About LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in several telecom companies in the UK, the Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies, and has pursued a strategy since 2016 to merge or partner with mobile-network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.